Avocado and Postprandial Responses

March 24, 2025 updated by: Jana Kraft, University of Vermont Medical Center

Acute Avocado Consumption on Postprandial Glycemic and Appetite/Satiety Responses

The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.

The investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:

  1. Whole-wheat bread and strawberry jam
  2. Whole-wheat bread, strawberry jam, and avocado
  3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)

Participants will undergo 3 test periods, each separated by a week. Each test period consists of one day with set meals that the investigators will provide (breakfast, lunch, and dinner), and then the next morning, participants will eat a breakfast meal and have blood drawn several times over 4 hours.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Clinical Research Project Manager
  • Phone Number: 802-656-8827
  • Email: foodstudy@uvm.edu

Study Locations

  • United States
    • Vermont
      • Burlington, Vermont, United States, 05405
        • Recruiting
        • Clinical Research Center, University of Vermont Medical Center
        • Contact:
          • Clinical Research Project Manager
          • Phone Number: 802-656-8827
          • Email: foodstudy@uvm.edu
        • Contact:
          • Jana Kraft, Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Biological sex males or females
  • Age 21 to 65 years
  • BMI between 18.5 and 34.9 kg/m2

Exclusion Criteria:

  • Actively pregnant or lactating women
  • Diagnosis of prediabetes or diabetes (fasting glucose >100 mg/dL)
  • Current diagnosis of uncontrolled hypertension (systolic BP: >160 mmHg, diastolic BP: >95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month
  • Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol >200 mg/dL, fasting triglycerides >200 mg/dL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month
  • Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus)
  • History of bariatric or certain other surgeries related to weight control
  • Any medication used to lower blood glucose/antidiabetic medications [including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors] as well as medications affecting weight, appetite/hunger or gut motility.
  • Smoking or use of other tobacco products (during 6 months prior to the start of the study)
  • Antibiotic use during the intervention or for 3 weeks prior to any treatment period
  • History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets)
  • Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence
  • Body weight loss of >10% within the last 6 months prior to study start
  • Unable or unwilling to give informed consent or communicate with study staff
  • Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
  • Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
  • Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Negative control breakfast
Participants will receive a breakfast with bread and jam, no avocado.
Other: Negative control
Participants will be given a breakfast meal with 76 grams of bread and 60 grams of jam per 2000 daily calories.
Experimental: Avocado addition breakfast
Participants will receive a breakfast with bread, jam, and avocado.
Other: Avocado
Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 84 grams of avocado per 2000 daily calories.
Active Comparator: Fat and fiber control breakfast
Participants will receive a breakfast with bread and jam, no avocado. The breakfast meal will be enriched with fat and fiber to mimic that of an avocado.
Other: Fat and fiber addition
Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 13 grams of fat (mix of high-oleic safflower oil, safflower oil, palm oil, and macadamia nut oil) and 5.5 grams of fiber (mix of cellulose and pectin) per 2000 daily calories.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diet-induced changes in postprandial glucose tolerance
Time Frame: 60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point
Blood glucose and insulin concentrations will be measured.
60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diet-induced changes in postprandial satiety hormones
Time Frame: 60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point
Blood ghrelin, peptide YY, glucagon-like peptide (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), leptin, and adiponectin concentrations will be measured.
60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Vermont Medical Center

Collaborators

Avocado Nutrition Center

Investigators

  • Principal Investigator: Jana Kraft, Ph.D., University of Vermont

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2025

Primary Completion (Estimated)

February 1, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

February 4, 2025

First Submitted That Met QC Criteria

February 4, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 28, 2025

Last Update Submitted That Met QC Criteria

March 24, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • STUDY00003379

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Negative control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe